Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in Patients With Platinum-Resistant Recurrent Ovarian Cancer By Ogkologos - April 23, 2026 4 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-ov65/KEYNOTE-B96 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Serplulimab Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR “Selfless and Incredible” Mother Leaves Behind Five Children After Battling Breast... November 25, 2020 Surgery for Recurrent Ovarian Cancer Does Not Improve Survival December 10, 2019 High Response Rates Observed Following KTE-X19 CAR T-Cell Therapy in Adults... June 15, 2021 4 Steps We Can All Take on World Cancer Day to... February 3, 2023 Load more HOT NEWS Healthy and Delicious Figs EMA Recommends Extension of Indications for Selumetinib Paramedical Tattoo Artist Creates Realistic Nipple Tattoos For Breast Cancer Survivors... Cancer Prevention Message Is Key for HPV Vaccination Discussions with Parents
